UPDATED: Takeda's manufacturing site in Belgium gets a €300M boost for plasma therapy production - Endpoints News

While phar­ma gi­ant Take­da has been ex­pand­ing its pres­ence in R&D and man­u­fac­tur­ing through­out the US and Asia over the past year, its lat­est move will see the com­pa­ny mak­ing a nine-fig­ure in­vest­ment in Eu­rope.

Take­da will pump €300 mil­lion ($299 mil­lion) in­to ex­pand­ing its man­u­fac­tur­ing site in Lessines, Bel­gium, a city around 30 miles south­west of Brus­sels. The ex­pan­sion will aim to in­crease the man­u­fac­tur­ing of plas­ma-de­rived ther­a­pies. Take­da al­so said that this is the largest in­vest­ment the com­pa­ny had made in Bel­gium.

Ge­of­frey Pot

The ex­pan­sion will con­sist of a new pro­duc­tion fa­cil­i­ty and ware­house. Ac­cord­ing to Ge­of­frey Pot, the gen­er­al man­ag­er of the Take­da Lessines site, in an email to End­points News, the ex­pan­sion will con­sist of 2,626 square me­ters and will be com­plet­ed by the end of 2023. How­ev­er af­ter the nec­es­sary tests and reg­u­la­to­ry ap­provals are met, the site ex­pects to be­gin pro­duc­tion by 2026.

The site it­self has been in op­er­a­tion for 50 years and has pro­duced plas­ma ther­a­pies, along with fill­ing and pack­ing the treat­ments. The site main­ly pro­duces plas­ma ther­a­pies for im­mun­od­e­fi­cien­cy dis­eases as well as treat­ments for rare dis­eases such as bleed­ing dis­or­ders and hered­i­tary an­gioede­ma.

This is al­so not the first in­vest­ment Take­da has made in the site. Ac­cord­ing to the gov­ern­ment web­site for the Bel­gian re­gion of Wal­lo­nia, Take­da in­vest­ed €118 mil­lion ($117 mil­lion) last year in a new pro­duc­tion line for pro­duc­ing ther­a­pies to treat Al­pha-1 an­tit­rypsin de­fi­cien­cy (AATD) as well as adding 100 jobs at the site.

Thomas Wozniews­ki

“Our Lessines site is an im­por­tant part of our glob­al man­u­fac­tur­ing net­work. The sig­nif­i­cant in­vest­ment in Lessines an­nounced to­day will strength­en the dig­i­tal­iza­tion of our man­u­fac­tur­ing sites where in­no­va­tion plays a key role in cre­at­ing a sus­tain­able pro­duc­tion en­vi­ron­ment,” Thomas Wozniews­ki, Take­da’s glob­al man­u­fac­tur­ing and sup­ply of­fi­cer, said in a state­ment.

Take­da al­so em­pha­sized the en­vi­ron­men­tal ef­forts for the ex­pan­sion as the com­pa­ny is plan­ning to re­duce its wa­ter us­age, be self-sus­tain­ing when it comes to elec­tric­i­ty and aims to pro­duce net-ze­ro car­bon emis­sions by 2030.

The in­vest­ment in Bel­gium is not the on­ly move that Take­da has made in its plas­ma ther­a­py unit. In Feb­ru­ary, Bob Nelsen-backed Re­silience es­tab­lished a part­ner­ship with Take­da’s plas­ma-de­rived ther­a­pies busi­ness unit to de­vel­op and man­u­fac­ture sev­er­al prod­ucts in its port­fo­lio out of its site in Mis­sis­sauga, On­tario, Cana­da.

Take­da has al­so been ex­pand­ing its foot­print in the US. Last year, the com­pa­ny broke ground on a 15,000-square-foot, $126 mil­lion man­u­fac­tur­ing fa­cil­i­ty in Thou­sand Oaks, CA. In June, Take­da al­so inked a 15-year lease to es­tab­lish a 600,000-square-foot R&D and of­fice HQ in Kendall Square in Cam­bridge, MA.

The sto­ry has been fur­ther up­dat­ed with de­tails from Take­da. 

Adblock test (Why?)

Read Again https://endpts.com/takedas-manufacturing-site-in-belgium-gets-a-e300m-boost-for-plasma-therapy-production/

Bagikan Berita Ini